Glen Harbor Capital Management LLC trimmed its stake in bluebird bio Inc (NASDAQ:BLUE) by 12.9% during the second quarter, HoldingsChannel.com reports. The fund owned 8,288 shares of the biotechnology company’s stock after selling 1,232 shares during the quarter. Glen Harbor Capital Management LLC’s holdings in bluebird bio were worth $1,301,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Commonwealth Equity Services LLC boosted its stake in bluebird bio by 24.7% in the first quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 383 shares in the last quarter. CIBC Asset Management Inc boosted its stake in bluebird bio by 28.5% in the second quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 395 shares in the last quarter. Winfield Associates Inc. boosted its stake in bluebird bio by 12.4% in the first quarter. Winfield Associates Inc. now owns 3,620 shares of the biotechnology company’s stock worth $618,000 after purchasing an additional 400 shares in the last quarter. Usca Ria LLC boosted its stake in bluebird bio by 10.3% in the first quarter. Usca Ria LLC now owns 6,720 shares of the biotechnology company’s stock worth $1,147,000 after purchasing an additional 630 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in bluebird bio by 9.7% in the second quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock worth $1,145,000 after purchasing an additional 646 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

In other bluebird bio news, Director James Mandell sold 1,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the transaction, the director now owns 1,568 shares of the company’s stock, valued at $236,407.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Davidson sold 3,000 shares of the stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $180.15, for a total value of $540,450.00. Following the completion of the transaction, the insider now directly owns 27,905 shares in the company, valued at approximately $5,027,085.75. The disclosure for this sale can be found here. Insiders sold 76,586 shares of company stock worth $12,525,882 in the last three months. Insiders own 3.00% of the company’s stock.

Shares of BLUE opened at $147.55 on Thursday. bluebird bio Inc has a 12-month low of $119.90 and a 12-month high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The firm had revenue of $7.80 million for the quarter, compared to analyst estimates of $10.68 million. During the same period last year, the company earned ($1.73) EPS. The company’s revenue was down 53.3% compared to the same quarter last year. research analysts predict that bluebird bio Inc will post -10.8 earnings per share for the current year.

A number of research firms have commented on BLUE. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald set a $122.00 price objective on bluebird bio and gave the stock a “sell” rating in a research note on Wednesday, September 5th. Piper Jaffray Companies reissued a “buy” rating on shares of bluebird bio in a research note on Thursday, August 2nd. Gabelli began coverage on bluebird bio in a research note on Thursday, July 12th. They issued a “buy” rating and a $239.00 price objective on the stock. Finally, William Blair reissued a “buy” rating on shares of bluebird bio in a research note on Wednesday, September 5th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $212.05.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Recommended Story: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.